Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 22, Art. 18 (pp. 262-270)    |    2021       

»

Chronic toxicity, specific activity and possible side effects of spironolactone

Vdovina G. P., Goldobina G. V., Bolotskaya N. V.,
Vasilyuk M. V., Burlutskaya A. A., Danilova V.K.

E. A. Wagner Perm State Medical University

Brief summary

The research purpose was to conduct a comparative study of chronic toxicity, specific activity and possible side effects of Spironolactone of the domestic manufacturer and the drug Verospiron. Materials and methods. The object of the study was the drug Spironolactone (Russia) in comparison with the standard drug Verospiron, tablets 25 mg, manufactured by "Gedeon Richter", Hungary. The investigations were carried out on white nonlinear rats of both sexes. The animals were divided into groups using the randomization method. Studies were conducted in accordance with the recommendations for preclinical study of drugs. The specific diuretic effect of the drugs was investigated. Their effect on the central nervous system of rats in an ?open field? chamber was studied. Results. Both drugs were equally well tolerated by animals. According to pathological studies, spironolactone and the reference drug lacked the irritating action of the gastrointestinal tract. Both drugs effectively increased diuresis in rats, but did not have a pronounced effect on the Central nervous system. Summary. Both drugs have the same specific activity.


Key words

Spironolactone, rats, diuresis, specific activity, side effects.

Reference list

1. Balashov A.I. Kak dobitsya lekarstvennoi nezavisimosti Rossii? EKO. 2016; 2(500): 145-58.


2. GrigorevaK. D. Lekarstvennoe importozameshenie - perspektivnoe napravlenie razvitiya rossiiskoi ekonomiki. Ypravlencheskoe konsyltirovanie.2018; 5(113):137-42


3. Podzolkov V.I., Dragomireckaya N.A. Antagonisti aldosterona. Sovremennie predstavleniya o mehanizmah deistviya i effektah spironolaktona. Racionalnaya Farmakoterapiya v Kardiologii.2017; 13(2) :263-269.


4. Chelcov V.V., Martinov A.I. Effektivnost blokatorov mineralokortikoidnih receptorov (spironolakton, eplerenon) pri hronicheskoi serdechnoi nedostatochnosti. Terapiya. 2016; 1(5): 67-74


5. Pavlova T. V. Spironolakton v terapii rezistentnoi arterialnoi gipertenzii. Kardiologiya: novosti, mneniya, obychenie. 2018; 6(3):24-30. DOI:10.24411/2309-1908-2018-13001


6. Plisuk A.G., Orlova Ya.A. Prakticheskie aspekti primeneniya antagonistov mineralokortikoidnih receptorov v lechenii arterialnoi gipertenzii. RMJ. 2017; 25 (25): 1846-49.


7. Shekotov V.V. Refrakternaya arterialnaya gipertenziya i problemi terapii. Permskii medicinskii jyrnal. 2016; 33(1) : 116-23.


8. GOST 33044-2014. Mejgosydarstvennii standart. Principi nadlejashei laboratornoi praktiki (vveden v deistvie Prikazom Rosstandarta ot 20.11.2014 N 1700-st).


9. Evropeiskaya konvenciya o zashite pozvonochnih jivotnih, ispolzyemih dlya eksperimentov ili v inih naychnih celyah: EST 123 ot 18 marta 1986 g., Strasbyrg;


10. Prikaz Minzdrava Rossii ot 01.04.2016 N 199n «Ob ytverjdenii Pravil nadlejashei laboratornoi praktiki» (Zaregistrirovano v Minuste Rossii 15.08.2016 43232);


11. Mashkovskii M. D. Lekarstvennie sredstva, 16-eizd. M.: Novaya volna; 2010.


12. Mironov A.N. (red.). Rykovodstvo po provedeniu doklinicheskih issledovanii lekarstvennih sredstv. Chast pervaya. M.: Grif i K; 2012.


13. Habriev R. Y. (red.). Rykovodstvo po eksperimentalnomy (doklinicheskomy) izycheniu novih farmakologicheskih veshestv. M.: Medicina; 2005.